Benitec Biopharma Inc. (BNTC) — Financial statements
Income statement, balance sheet, and cash flow for Benitec Biopharma Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 0.08↑2.7% | 0.07↑23.7% | 0.06 | |
| Cost of Revenue | 0.40↑15.5% | 0.34↓10.0% | 0.38↑4133.3% | 0.01↓92.7% | 0.12 | |
| Gross Profit | -0.40↓15.5% | -0.34↓12.1% | -0.31↓578.1% | 0.06↑200.0% | -0.06 | |
| Operating Expenses | ||||||
| R&D Expenses | 18↑17.4% | 16↑22.2% | 13↑13.3% | 11↑60.6% | 7 | |
| General & Administrative Expenses | 23 | 0.00 | 0.00↓100.0% | 7↑2.1% | 7 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 23↑252.6% | 7↑10.7% | 6↓9.7% | 7↑2.1% | 7 | |
| Other Expenses | -0.40 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 41↑85.9% | 22↑18.5% | 19↑4.8% | 18↑32.4% | 14 | |
| Total Costs & Expenses | 42↑84.8% | 23↑18.0% | 19↑6.9% | 18↑31.3% | 14 | |
| Operating Results | ||||||
| Operating Income | -42↓84.8% | -23↓18.4% | -19↓6.9% | -18↓31.3% | -14 | |
| Depreciation & Amortization | 0.07↓79.8% | 0.34↓10.0% | 0.38↓2.8% | 0.39↓7.5% | 0.42 | |
| EBITDA | -42↓94.8% | -21↓11.8% | -19↓7.2% | -18↓32.7% | -13 | |
| EBIT | -42↓92.0% | -22↓11.4% | -20↓7.4% | -18↓31.0% | -14 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↑263.5% | 0.90↑2839.4% | -0.03↓3.1% | -0.03↓433.3% | -0.01 | |
| Interest Income | 3↑263.5% | 0.90 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 0.03↑3.1% | 0.03↑433.3% | 0.01 | |
| Non-Operating Income | 0.00↑100.0% | -0.85↓289.1% | 0.45↑39.1% | 0.32↑15.0% | 0.28 | |
| Other Income / Expenses | 4↑354.3% | 0.85↑276.1% | -0.48↓35.9% | -0.35↓23.8% | -0.29 | |
| Income Before Tax | -38↓74.3% | -22↓11.2% | -20↓7.4% | -18↓31.2% | -14 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -38↓74.3% | -22↓11.2% | -20↓7.4% | -18↓31.2% | -14 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -38↓74.3% | -22↓11.2% | -20↓7.4% | -18↓31.2% | -14 | |
| Bottom-Line Net Income | -38↓69.5% | -22↓14.4% | -20↓7.4% | -18↓31.2% | -14 | |
| EPS (Basic) | -1.05↑60.8% | -2.68↑81.0% | -14.12↑26.9% | -19.31↑29.2% | -27.27 | |
| EPS (Diluted) | -1.05↑60.8% | -2.68↑81.0% | -14.12↑26.9% | -19.31↑29.2% | -27.27 | |
| Weighted Average Shares | 36↑252.9% | 10↑640.5% | 1↓27.9% | 2↑90.2% | 1 | |
| Weighted Average Diluted Shares | 36↑252.4% | 10↑641.5% | 1↓27.9% | 2↑90.2% | 1 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.